Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;10(4):e1001418.
doi: 10.1371/journal.pmed.1001418. Epub 2013 Apr 9.

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies

Collaborators, Affiliations

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies

Leigh F Johnson et al. PLoS Med. 2013.

Abstract

Background: Few estimates exist of the life expectancy of HIV-positive adults receiving antiretroviral treatment (ART) in low- and middle-income countries. We aimed to estimate the life expectancy of patients starting ART in South Africa and compare it with that of HIV-negative adults.

Methods and findings: Data were collected from six South African ART cohorts. Analysis was restricted to 37,740 HIV-positive adults starting ART for the first time. Estimates of mortality were obtained by linking patient records to the national population register. Relative survival models were used to estimate the excess mortality attributable to HIV by age, for different baseline CD4 categories and different durations. Non-HIV mortality was estimated using a South African demographic model. The average life expectancy of men starting ART varied between 27.6 y (95% CI: 25.2-30.2) at age 20 y and 10.1 y (95% CI: 9.3-10.8) at age 60 y, while estimates for women at the same ages were substantially higher, at 36.8 y (95% CI: 34.0-39.7) and 14.4 y (95% CI: 13.3-15.3), respectively. The life expectancy of a 20-y-old woman was 43.1 y (95% CI: 40.1-46.0) if her baseline CD4 count was ≥ 200 cells/µl, compared to 29.5 y (95% CI: 26.2-33.0) if her baseline CD4 count was <50 cells/µl. Life expectancies of patients with baseline CD4 counts ≥ 200 cells/µl were between 70% and 86% of those in HIV-negative adults of the same age and sex, and life expectancies were increased by 15%-20% in patients who had survived 2 y after starting ART. However, the analysis was limited by a lack of mortality data at longer durations.

Conclusions: South African HIV-positive adults can have a near-normal life expectancy, provided that they start ART before their CD4 count drops below 200 cells/µl. These findings demonstrate that the near-normal life expectancies of HIV-positive individuals receiving ART in high-income countries can apply to low- and middle-income countries as well. Please see later in the article for the Editors' Summary.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Life expectancies of patients starting ART, as proportions of life expectancies of HIV-negative adults.
Proportions are plotted by age at ART initiation and baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.
Figure 2
Figure 2. Proportion of individuals starting ART who are expected to die from causes unrelated to HIV.
Proportions are plotted by age at ART initiation and baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.
Figure 3
Figure 3. Life expectancies of patients with recorded ID, starting ART after 2006.
Life expectancies are plotted by age at ART initiation and baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.

References

    1. Hallett TB, Gregson S, Dube S, Mapfeka ES, Mugurungi O, et al. (2011) Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe. Sex Transm Infect 87: 621–628. - PMC - PubMed
    1. Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, et al. (2011) Economic returns to investment in AIDS treatment in low and middle income countries. PLoS ONE 6: e25310 doi:10.1371/journal.pone.0025310. - DOI - PMC - PubMed
    1. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, et al. (2006) The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44: 990–997. - PubMed
    1. May M, Gompels M, Delpech V, Porter K, Post F, et al. (2011) Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 343: d6016. - PMC - PubMed
    1. McDavid Harrison K, Song R, Zhang X (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immun Defic Syndr 53: 124–130. - PubMed

Publication types

Substances